Sign up to save your podcasts
Or
Share Lower-Dose Combo Immunotherapy Promising for Advanced Melanoma
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Lower-Dose Combo Immunotherapy Promising for Advanced Melanoma
Dr Jeffrey S. Weber reviews data from an open-label phase 1/2 trial assessing the efficacy and safety of combination pembrolizumab and reduced-dose ipilimumab in patients with advanced melanoma.
View all episodes
By MedscapeDr Jeffrey S. Weber reviews data from an open-label phase 1/2 trial assessing the efficacy and safety of combination pembrolizumab and reduced-dose ipilimumab in patients with advanced melanoma.